- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05316727
Electronic Nicotine Delivery Devices and Potential Progression to Acute Lung Injury (ENDALI)
Study Overview
Status
Detailed Description
Participants will be consented and undergo collection of data and specimens as listed below.
- Vaping use will be determined by history.
- No administration, dispensing or use of any vape product will take place as part of the study.
Experimental procedures:
Respiratory questionnaires and data review:
Detailed data regarding smoking history, illicit drug use, ART and other medications, and medical history are obtained using standardized questionnaires and medical record review. The Modified Medical Research Council Dyspnea scale (MMRC), the St. George's Questionnaire(SGQT), Pulmonary questionnaire (PQ) and a Vaping questionnaire will be administered. These are paper and pencil questionnaires that inquire about respiratory symptoms, quality of life, and other lung related issues. Laboratory data including CD4 cell counts and HIV viral levels are obtained from the medical record.
Blood Sample collection:
The subject will be asked to provide a blood sample by venipuncture of approximately 110mls (7.4 tablespoon) at this study visit. The purpose of this collection is to have blood processed for serum, plasma, and PBMCS, and a portion stored for RNA to be used for future use. A hemoglobin and carboxyhemoglobin will be done in order to calculate the DLCO. A CBC will be done to determine overall health and possible infections.
Saliva Collection: Participants will be asked to produce saliva and spit it into a sterile conical.
Stool collection: The investigator will ask participants to provide a stool sample. The subject will be instructed on how to collect a stool specimen at home. The investigator will give the subject instructions and a kit that will provide all the supplies needed to collect the stool and return it via mail at their convenience.
Lung function testing (PFT):
If a PFT was completed for a research study in the past month, that data will be used instead of repeating the test. The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards. All testing will be reviewed by a physician associated with this study. If any concerns or abnormal results are discovered during this testing, a member of the research team will notify the subject or the subject's primary care physician, who will assess the need to provide additional evaluation.
Pregnancy Test: A urine pregnancy test will be performed on all women of child bearing potential. Men, and women who are post menopausal for at least 1 year or have been surgically made sterile will not have a pregnancy test.
Collection of the vape product used by the subject. Declining participation in this collection does not mean the subject can't participate in the study.
The product will be sent to the investigators research labs for potential chemical analysis.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Cathy J Kessinger
- Phone Number: 412-624-8330
- Email: kessingercj@upmc.edu
Study Contact Backup
- Name: Shawna Blacka
- Phone Number: 412-383-5972
- Email: reekies@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh department of medicine division of Pulmonary, Allergy and Critical Care medicine
-
Contact:
- Cathy J Kessinger, RN
- Phone Number: 412-624-8330
- Email: kessingercj@upmc.edu
-
Principal Investigator:
- Alison M Morris, MD,MS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
The investigators will leverage resources from an ongoing cohort of people living with HIV (PLWH) and HIV-uninfected community dwelling individuals as well as a growing dataset of individuals hospitalized with EVALI.
individuals, males or females in all races, ethnicities, and socioeconomic backgrounds greater than 18 years of age.
Description
Inclusion Criteria:
- Men and women age 18 to 80
- Participant in a previous HLRC study, or a participant in the HIV PACT clinic or referred by a PACCM physician
- At least weekly vape use over the past 3 months
- OR No previous history of vape use and no current history of smoking tobacco for controls
- negative pregnancy test (for women of child barring capabilities)
Exclusion Criteria:
- pregnancy or breast-feeding (urine pregnancy done on all females of child bearing potential- - - males and females who are at least 1 year post menopausal or surgically sterile will not be tested)
- Contraindication to pulmonary function testing (i.e. abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.).
- Increasing respiratory symptoms or febrile (temperature >100.40F [380C]) within 4 weeks of study entry.
- Acute cardiopulmonary issue in the past 4 months.
- Uncontrolled hypertension at screening visit (systolic > 180 mm Hg or diastolic > 100 mm Hg) from an average of two or more readings. Subject may return for screening after blood pressure is controlled.
- Active cancer requiring systemic chemotherapy or radiation.
- Active infection of lungs, brain, or abdomen.
- Intravenous drug use or alcohol use that will impair ability to complete study investigations in the opinion of the investigator.
- subjects with an upper or lower respiratory tract infection
- Persons who have tested positive for Covid 19 in the past 4 weeks.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Vaping
At least weekly vape use over the past 3 months of the subjects unspecified product
|
Non vapers
No previous history of vape use and no current history of smoking tobacco for controls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in pulmonary function comparing vaping and non vaping participants (1)
Time Frame: Before bronchodilation
|
The routine lung function endpoints of FVC, will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
Before bronchodilation
|
Difference in pulmonary function comparing vaping and non vaping participants (2)
Time Frame: Before bronchodilation
|
The routine lung function endpoints of FEV1, will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
Before bronchodilation
|
Difference in pulmonary function comparing vaping and non vaping participants (3)
Time Frame: Before bronchodilation
|
The routine lung function endpoints of FEV1/FVC, will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
Before bronchodilation
|
Difference in pulmonary function comparing vaping and non vaping participants (4)
Time Frame: Before bronchodilation
|
The routine lung function endpoints of FEF25-75%, will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
Before bronchodilation
|
Difference in pulmonary function comparing vaping and non vaping participants (PB1)
Time Frame: within 10 minutes after bronchodilation
|
The routine lung function endpoints of FVC, will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
within 10 minutes after bronchodilation
|
Difference in pulmonary function comparing vaping and non vaping participants (PB2)
Time Frame: within 10 minutes after bronchodilation
|
The routine lung function endpoints of FEV1 will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
within 10 minutes after bronchodilation
|
Difference in pulmonary function comparing vaping and non vaping participants (PB3)
Time Frame: within 10 minutes after bronchodilation
|
The routine lung function endpoints of FEV1/FVC, will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
within 10 minutes after bronchodilation
|
Difference in pulmonary function comparing vaping and non vaping participants (PB4)
Time Frame: within 10 minutes after bronchodilation
|
The routine lung function endpoints of FEF25-75%, will be measured with the flow-volume loop recorder on a NDD Easy One Pro testing system.
|
within 10 minutes after bronchodilation
|
Difference in diffusion capacity comparing vaping and non vaping participants
Time Frame: within 15 minutes after bronchodilation
|
The routine lung function diffusion lung capacity for carbon monoxide (DLCO) will be measured.
|
within 15 minutes after bronchodilation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in inflammation
Time Frame: collected at one visit -will complete analysis in 2 years.
|
The investigators will determine inflammation in sputum peripheral cytokine responses
|
collected at one visit -will complete analysis in 2 years.
|
Measurement of the inflammone in vaping and non vaping persons
Time Frame: collection at one visit - will complete analysis in 2 years.
|
The investigators will use this cohort to evaluate biomarkers (type to be determined) of inflammation to determine if the investigator can identify specific HIV vapors phenotypes using novel decision tree analyses.
The investigator will examine relationship of the inflammatory signature associated with vaping
|
collection at one visit - will complete analysis in 2 years.
|
comparison of microbial communities in stool
Time Frame: one stool collection at the subjects convenience - will complete analysis in 2 years.
|
The investigators will use stool collected to compare bacterial function between vapers and non vapers
|
one stool collection at the subjects convenience - will complete analysis in 2 years.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alison Morris, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY20020151
- 5R01HL140963-04 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Electronic Cigarette Use
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | E-Cig UseUnited States
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA)Completed
-
Florida International UniversityCompletedElectronic Cigarette UseUnited States
-
Michigan Technological UniversityCompleted
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)RecruitingElectronic Cigarette UseUnited States